Ionway to Build First Production Plant in Poland
By Andrea Figueras
Ionway, the electric-vehicle battery materials joint venture of Umicore and Volkswagen's PowerCo, plans to build its first cathode-active-material (CAM) plant in Nysa, Poland.
The facility will be adjacent to Umicore's existing CAM plant, which will allow Ionway to benefit from Umicore's know-how and to access renewable energy to power its production, the joint venture said over the weekend.
The construction of the plant will start once Ionway gets the corresponding permits, a process that it said is ongoing.
The investment in Poland will create about 900 jobs in Nysa toward the end of the decade and will receive support from the Polish government, which is offering 350 million euros ($370.6 million) in cash grants for a total investment of up to EUR1.7 billion (reduced to EUR1.35 billion after grants) by the end of the decade.
Ionway aims to grow its annual production capacity to 160 gigawatt-hour by the end of the decade, which corresponds to 2.2 million battery-electric vehicles, it said.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
October 09, 2023 01:47 ET (05:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track